Abstract
Introduction
Resection of the capsule of the pancreas is part of the radical operation proposed by oriental authors for the treatment of gastric cancer. It is unclear; however, if resection of the capsule is a safe procedure or even if it is necessary. This study aims to assess in patients treated for gastric cancer the occurrence of: (a) pancreatic fistula and (b) metastasis to the pancreatic capsule.
Methods
We studied 80 patients (mean age 61 years, 42 males) submitted to gastrectomy with resection of the pancreatic capsule by hydrodissection. Patients with pancreatic disease, tumoral invasion of the pancreas, submitted to concomitant splenectomy, or anastomotic leakage were excluded. The tumor was located in the distal third of the stomach in 60% of the patients, in the middle third in 27%, and proximally in 12%. Total gastrectomy was performed in 27% of the cases and partial gastrectomy in 73%. In all patients, amylase activity in the drainage fluid was measured on day 2. If initial measurement was abnormal, subsequent measurements were performed in alternated days until normalization. Pancreatic fistula was defined as amylase levels greater than 600. In 25 of these patients (mean age 53 years, 16 males), the pancreatic capsule was histologically analyzed for metastasis.
Results
Pancreatic fistula was diagnosed in eight (10%) patients. The mean amylase level was 5,863. Normalization of amylase levels was achieved within 7 days in all patients. No patient developed clinical signs of fistula besides abnormal amylase levels in the drainage fluid, such as intra-abdominal abscesses. Pancreatic fistula was associated to younger age (p = 0.03) but not to gender (p = 0.1), tumor location (p = 0.6), and type of gastrectomy (p = 0.8). Metastasis to the pancreatic capsule was not identified.
Conclusion
In conclusion, resection of the pancreatic capsule must be discouraged due to subclinical pancreatic fistula in a significant number of the cases and absence of metastasis.
Similar content being viewed by others
References
Davis PA, Sano T. The difference in gastric cancer between Japan, USA and Europe: what are the facts? what are the suggestions? Crit Rev Oncol Hematol 2001;40(1):77–94. doi:10.1016/S1040-8428(00)00131-1.
Sasagawa T, Solano H, Vega W, Mena F. The effectiveness of extended lymph node dissection for gastric cancer performed in Costa Rica under the supervision of a Japanese surgeon: a comparison with surgical results in Japan. Am J Surg 2008;195(1):53–60. doi:10.1016/j.amjsurg.2007.01.028.
Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol 2007;14(2):317–328. doi:10.1245/s10434-006-9218-2.
Oñate-Ocaña LF, Aiello-Crocifoglio V, Mondragón-Sánchez R, Ruiz-Molina JM. Survival benefit of D2 lymphadenectomy in patients with gastric adenocarcinoma. Ann Surg Oncol. 2000;7(3):210–217. doi:10.1007/BF02523656.
Sakakibara N. Atlas of Advanced Gastric Surgery Techniques. Amsterdam: Harwood, 1997.
Danielson H, Kokkola A, Kiviluoto T, Sirén J, Louhimo J, Kivilaakso E et al. Clinical outcome after D1 vs D2–3 gastrectomy for treatment of gastric cancer. Scand J Surg 2007;96(1):35–40.
Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, Welvaart K, van Krieken JH, Meijer S, Plukker JT, van Elk PJ, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H, Sasako M. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004;22(11):2069–2077.
Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, Cook P. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996;347(9007):995–999.
Ichikawa D, Kurioka H, Yamaguchi T, Koike H, Okamoto K, Otsuji E et al. Postoperative complications following gastrectomy for gastric cancer during the last decade. Hepatogastroenterology 2004;51(56):613–617.
D’Amato A, Santella S, Cristaldi M, Gentili V, Pronio A, Montesani C. The role of extended total gastrectomy in advanced gastric cancer. Hepatogastroenterology 2004;51(56):609–612.
Kunisaki C, Makino H, Suwa H, Sato T, Oshima T, Nagano Y et al. Impact of splenectomy in patients with gastric adenocarcinoma of the cardia. J Gastrointest Surg 2007;11(8):1039–1044. doi:10.1007/s11605-007-0186-z.
Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138:8–13. doi:10.1016/j.surg.2005.05.001.
Japanese Gastric Cancer Association. Gastric Cancer Treatment Guidelines. Tokyo: Kanehara, 2004, pp 9–10.
Yamamura Y, Ito S, Mochizuki Y, Nakanishi H, Tatematsu M, Kodera Y. Distribution of free cancer cells in the abdominal cavity suggests limitations of bursectomy as an essential component of radical surgery for gastric carcinoma. Gastric Cancer 2007;10(1):24–28. doi:10.1007/s10120-006-0404-5.
Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, Hasegawa S et al. Is bursectomy necessary for patients with gastric cancer invading the serosa? Hepatogastroenterology 2004;51(59):1524–1526.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Herbella, F.A., Tineli, A.C., Wilson, J.L. et al. Gastrectomy and Lymphadenectomy for Gastric Cancer: is the Pancreas Safe?. J Gastrointest Surg 12, 1912–1914 (2008). https://doi.org/10.1007/s11605-008-0572-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11605-008-0572-1